Literature DB >> 32462735

Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.

Paal W Wallace1, Catleen Conrad1, Sascha Brückmann2, Ying Pang3, Eduardo Caleiras4, Masanori Murakami5, Esther Korpershoek6, Zhengping Zhuang7, Elena Rapizzi8, Matthias Kroiss9, Volker Gudziol10,11, Henri Jlm Timmers12, Massimo Mannelli8, Jens Pietzsch13,14, Felix Beuschlein5,15, Karel Pacak3, Mercedes Robledo16, Barbara Klink17,18, Mirko Peitzsch1, Anthony J Gill19,20,21, Arthur S Tischler22, Ronald R de Krijger23,24, Thomas Papathomas25, Daniela Aust26, Graeme Eisenhofer1,27, Susan Richter1.   

Abstract

Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a hereditary background in over one-third of patients. Mutations in succinate dehydrogenase (SDH) genes increase the risk for PPGLs and several other tumours. Mutations in subunit B (SDHB) in particular are a risk factor for metastatic disease, further highlighting the importance of identifying SDHx mutations for patient management. Genetic variants of unknown significance, where implications for the patient and family members are unclear, are a problem for interpretation. For such cases, reliable methods for evaluating protein functionality are required. Immunohistochemistry for SDHB (SDHB-IHC) is the method of choice but does not assess functionality at the enzymatic level. Liquid chromatography-mass spectrometry-based measurements of metabolite precursors and products of enzymatic reactions provide an alternative method. Here, we compare SDHB-IHC with metabolite profiling in 189 tumours from 187 PPGL patients. Besides evaluating succinate:fumarate ratios (SFRs), machine learning algorithms were developed to establish predictive models for interpreting metabolite data. Metabolite profiling showed higher diagnostic specificity compared to SDHB-IHC (99.2% versus 92.5%, p = 0.021), whereas sensitivity was comparable. Application of machine learning algorithms to metabolite profiles improved predictive ability over that of the SFR, in particular for hard-to-interpret cases of head and neck paragangliomas (AUC 0.9821 versus 0.9613, p = 0.044). Importantly, the combination of metabolite profiling with SDHB-IHC has complementary utility, as SDHB-IHC correctly classified all but one of the false negatives from metabolite profiling strategies, while metabolite profiling correctly classified all but one of the false negatives/positives from SDHB-IHC. From 186 tumours with confirmed status of SDHx variant pathogenicity, the combination of the two methods resulted in 185 correct predictions, highlighting the benefits of both strategies for patient management.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Entities:  

Keywords:  Krebs cycle metabolites; LC-MS/MS; diagnostics; linear discriminant analysis; mass spectrometry; metabolite profiling; multi-observer; prediction models; succinate to fumarate ratio; variants of unknown significance

Mesh:

Substances:

Year:  2020        PMID: 32462735      PMCID: PMC7548960          DOI: 10.1002/path.5472

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   9.883


  30 in total

Review 1.  Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.

Authors:  Rodrigo A Toledo; Nelly Burnichon; Alberto Cascon; Diana E Benn; Jean-Pierre Bayley; Jenny Welander; Carli M Tops; Helen Firth; Trish Dwight; Tonino Ercolino; Massimo Mannelli; Giuseppe Opocher; Roderick Clifton-Bligh; Oliver Gimm; Eamonn R Maher; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Patricia L M Dahia
Journal:  Nat Rev Endocrinol       Date:  2016-11-18       Impact factor: 43.330

Review 2.  Succinate dehydrogenase (SDH)-deficient neoplasia.

Authors:  Anthony J Gill
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

3.  Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma.

Authors:  Trisha Dwight; Edward Kim; Talia Novos; Roderick J Clifton-Bligh
Journal:  Horm Metab Res       Date:  2019-07-15       Impact factor: 2.936

4.  Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas.

Authors:  Susan Richter; Barbara Klink; Brit Nacke; Aguirre A de Cubas; Anastasios Mangelis; Elena Rapizzi; Matthias Meinhardt; Christina Skondra; Massimo Mannelli; Mercedes Robledo; Mario Menschikowski; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2015-12-11       Impact factor: 5.958

5.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

6.  Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.

Authors:  Suman Ghosal; Shaoli Das; Ying Pang; Melissa K Gonzales; Thanh-Truc Huynh; Yanqin Yang; David Taieb; Joakim Crona; Uma T Shankavaram; Karel Pacak
Journal:  Int J Cancer       Date:  2019-10-11       Impact factor: 7.316

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

8.  Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.

Authors:  Edward Kim; Michael Jp Wright; Loretta Sioson; Talia Novos; Anthony J Gill; Diana E Benn; Christopher White; Trisha Dwight; Roderick J Clifton-Bligh
Journal:  Mol Genet Metab Rep       Date:  2016-12-30

Review 9.  Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations.

Authors:  Lucie Evenepoel; Thomas G Papathomas; Niels Krol; Esther Korpershoek; Ronald R de Krijger; Alexandre Persu; Winand N M Dinjens
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

10.  Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.

Authors:  Susan Richter; Laura Gieldon; Ying Pang; Mirko Peitzsch; Thanh Huynh; Rocio Leton; Bruna Viana; Tonino Ercolino; Anastasios Mangelis; Elena Rapizzi; Mario Menschikowski; Daniela Aust; Matthias Kroiss; Felix Beuschlein; Volker Gudziol; Henri Jlm Timmers; Jacques Lenders; Massimo Mannelli; Alberto Cascon; Karel Pacak; Mercedes Robledo; Graeme Eisenhofer; Barbara Klink
Journal:  Genet Med       Date:  2018-07-27       Impact factor: 8.822

View more
  7 in total

Review 1.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

2.  Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors.

Authors:  Juliane März; Max Kurlbaum; Oisin Roche-Lancaster; Timo Deutschbein; Mirko Peitzsch; Cornelia Prehn; Dirk Weismann; Mercedes Robledo; Jerzy Adamski; Martin Fassnacht; Meik Kunz; Matthias Kroiss
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

Review 3.  New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.

Authors:  Sakshi Jhawar; Yasuhiro Arakawa; Suresh Kumar; Diana Varghese; Yoo Sun Kim; Nitin Roper; Fathi Elloumi; Yves Pommier; Karel Pacak; Jaydira Del Rivero
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 4.  Succinate Dehydrogenase, Succinate, and Superoxides: A Genetic, Epigenetic, Metabolic, Environmental Explosive Crossroad.

Authors:  Paule Bénit; Judith Goncalves; Riyad El Khoury; Malgorzata Rak; Judith Favier; Anne-Paule Gimenez-Roqueplo; Pierre Rustin
Journal:  Biomedicines       Date:  2022-07-25

Review 5.  Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours.

Authors:  Paul Benjamin Loughrey; Federico Roncaroli; Estelle Healy; Philip Weir; Madhu Basetti; Ruth T Casey; Steven J Hunter; Márta Korbonits
Journal:  Endocr Relat Cancer       Date:  2022-09-02       Impact factor: 5.900

6.  Immunohistochemistry and Mutation Analysis of SDHx Genes in Carotid Paragangliomas.

Authors:  Anastasiya V Snezhkina; Dmitry V Kalinin; Vladislav S Pavlov; Elena N Lukyanova; Alexander L Golovyuk; Maria S Fedorova; Elena A Pudova; Maria V Savvateeva; Oleg A Stepanov; Andrey A Poloznikov; Tatiana B Demidova; Nataliya V Melnikova; Alexey A Dmitriev; George S Krasnov; Anna V Kudryavtseva
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

Review 7.  Personalized Management of Pheochromocytoma and Paraganglioma.

Authors:  Svenja Nölting; Nicole Bechmann; David Taieb; Felix Beuschlein; Martin Fassnacht; Matthias Kroiss; Graeme Eisenhofer; Ashley Grossman; Karel Pacak
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 19.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.